An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients

Roche

Status: Completed

Conditions: Cytomegalovirus Infections

Study type: Observational

Funder types: Industry

Identifiers

NCT02062294

ML25224

Details and patient eligibility

About

This retrospective review will evaluate the efficacy of Valcyte (valganciclovir) in preventing Cytomegalovirus (CMV) disease in D+/R- liver transplant recipients. Data from eligible patients will be collected for the 6 months following transplantation.

Enrollment: 14 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Liver transplant recipients, >/= 16 years of age
• Transplantation between January 2004 and June 2009
• CMV seronegative recipient (R-) who received a liver transplant from a seropositive donor (D+)
• Valganciclovir therapy for at least 70 days beginning within 10 days post transplantation
• Assessment of CMV disease status within the first 6 months post transplantation

Exclusion criteria

• None

Trial design

14 participants in 1 patient group

Cohort